Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

The New England Journal of Medicine
Alexander DrilonDavid M Hyman

Abstract

Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. We enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety. A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion-positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progressi...Continue Reading

References

Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David JackmanVincent A Miller
Jan 27, 2012·Science Translational Medicine·Ryohei KatayamaJeffrey A Engelman
Oct 29, 2013·Nature Medicine·Aria VaishnaviRobert C Doebele
Jan 22, 2014·Nature Communications·Thomas WiesnerBoris C Bastian
Sep 11, 2014·Nature Communications·Nicolas StranskyChristoph Lengauer
Dec 21, 2014·Cancer Discovery·Aria VaishnaviRobert C Doebele
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Feb 18, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DrilonA L Ho

❮ Previous
Next ❯

Citations

Mar 14, 2018·Nature Reviews. Clinical Oncology·Peter Sidaway
Feb 22, 2018·The New England Journal of Medicine·Fabrice André
Apr 5, 2018·Cancers·Allison M Lange, Hui-Wen Lo
May 10, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M Kuderer, Gary H Lyman
May 25, 2018·Expert Opinion on Drug Discovery·Ecaterina Ileana DumbravaTimothy A Yap
Apr 24, 2018·The American Journal of Surgical Pathology·Erin R RudzinskiJessica L Davis
Apr 24, 2018·The American Journal of Surgical Pathology·Cecilia LezcanoKlaus J Busam
Jun 20, 2018·The Journal of Clinical Investigation·Justin TaylorOmar Abdel-Wahab
Aug 8, 2018·International Journal of Molecular Sciences·Carlotta AntoniottiChiara Cremolini
Aug 14, 2018·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·Samuel RackRobert Metcalf
Sep 7, 2018·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Matthew TorreSanda Alexandrescu
Jul 31, 2018·Ophthalmic Plastic and Reconstructive Surgery·John G BortzTatyana Milman
Jul 28, 2018·Blood·Yana Pikman, Kimberly Stegmaier
Sep 7, 2018·Advances in Anatomic Pathology·Yin P Hung, Lynette M Sholl
Nov 13, 2018·JAMA Pediatrics·Jonathan KimmelmanHolly Fernandez Lynch
Nov 13, 2018·JAMA Oncology·S Gail Eckhardt, Christopher Lieu
Nov 20, 2018·F1000Research·Jennifer Choe, Richard Riedel
Oct 24, 2018·Expert Review of Anticancer Therapy·Theodore W Laetsch, Douglas S Hawkins
Dec 13, 2018·Expert Opinion on Investigational Drugs·Sreenivasa ChandanaDaruka Mahadevan
Nov 2, 2018·Genes, Chromosomes & Cancer·William J Anderson, Jason L Hornick
Jan 9, 2019·Expert Review of Molecular Diagnostics·Andrew J McKenzieHoward Burris
Jan 10, 2019·International Journal of Molecular Sciences·Shinji MiwaHiroyuki Tsuchiya
Feb 2, 2019·Pathology International·Annabelle RemouéArnaud Uguen
Jan 19, 2019·Molecular Oncology·Christian H Brandts
Feb 5, 2019·Current Oncology Reports·Munveer S Bhangoo, Darren Sigal
Jan 10, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D S HongR C Doebele
Feb 12, 2019·Cell Death & Disease·Sabrina BlondyAurélie Perraud
Nov 20, 2018·The American Journal of Surgical Pathology·Martin S TaylorVikram Deshpande
Feb 5, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R CondorelliN C Turner
Jan 31, 2019·Molecular Oncology·Elena GarraldaJosep Tabernero
Feb 27, 2019·Current Oncology Reports·Patrick R HallidayTrever G Bivona
Feb 26, 2019·Journal of Surgical Oncology·Jaideep SandhuMarwan Fakih
Feb 10, 2019·Journal of Personalized Medicine·Stergios BoussiosNicholas Pavlidis
Mar 12, 2019·Pediatric Blood & Cancer·David S Shulman, Steven G DuBois
Jan 19, 2019·Journal of the National Cancer Institute·Iwei YehMaryam M Asgari
Dec 27, 2018·The American Journal of Surgical Pathology·Jessica L DavisErin R Rudzinski
Dec 7, 2018·The American Journal of Surgical Pathology·Fumito YamazakiAkihiko Yoshida
Mar 23, 2019·Expert Opinion on Investigational Drugs·Stefano CavalieriSalvatore Alfieri
May 1, 2019·Nature Medicine·Christophe Le TourneauMaud Kamal
May 13, 2018·Current Treatment Options in Oncology·Satya DasRichard M Goldberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.